Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 7/20 | 0.72 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.72 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.67 |
| ▸ | NPC1 | O15118 | 5/20 | 0.67 |
| ▸ | MEN1 | O00255 | 4/20 | 0.67 |
| ▸ | TP53 | P04637 | 2/20 | 0.67 |
| ▸ | NR2F2 | P24468 | 1/20 | 0.67 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.67 |
| ▸ | HTT | P42858 | 1/20 | 0.67 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.67 |
| ▸ | KCNQ3 | O43525 | 4/20 | 0.64 |
| ▸ | KCNQ2 | O43526 | 4/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.64 |
| ▸ | LMNA | P02545 | 2/20 | 0.64 |
| ▸ | KCNE1 | P15382 | 2/20 | 0.60 |
| ▸ | KCNQ1 | P51787 | 2/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.59 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2302037 | 0.87 | KCNQ3 (0.67) | RAB9ASMN1; SMN2KMT2ANPC1MEN1 | |
| SCHEMBL3309155 | 0.87 | PPARG (0.60) | RAB9ASMN1; SMN2P4HTMKMT2ANPC1 | |
| SCHEMBL3309149 | 0.87 | LMNA (0.58) | RAB9ASMN1; SMN2P4HTMKMT2ANPC1 | |
| SCHEMBL2302748 | 0.87 | RAB9A (0.74) | RAB9ASMN1; SMN2KMT2ANPC1MEN1 | |
| SCHEMBL31254487 | 0.85 | NPC1 (0.66) | RAB9ASMN1; SMN2P4HTMKMT2ANPC1 | |
| SCHEMBL2303815 | 0.84 | KCNQ3 (0.77) | RAB9ASMN1; SMN2KMT2ANPC1MEN1 | |
| SCHEMBL8361559 | 0.84 | RAB9A (1.00) | RAB9ASMN1; SMN2P4HTMKMT2ANPC1 | |
| SCHEMBL3788719 | 0.83 | SMN1; SMN2 (0.64) | RAB9ASMN1; SMN2KMT2ANPC1MEN1 | |
| SCHEMBL13210715 | 0.83 | P4HTM (0.78) | RAB9ASMN1; SMN2P4HTMKMT2ANPC1 | |
| SCHEMBL6631748 | 0.83 | RAB9A (0.64) | RAB9ASMN1; SMN2KMT2AMEN1KCNQ3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9133143-B2 | (3-fluoro-2-hydroxy)propyl-functionalized aryl derivatives or pharmaceutically acceptable salts thereof, method for preparing same, and pharmaceutical composition containing same as active ingredient for the diagnosis or treatment of neurodegenerative brain diseases | FUTURECHEM CO., LTD. (KR) | 2015-09-15 | — | — | US | disclosed |
| CN-102725285-B | (3-fluoro-2-hydroxy) propyl-functional aryl derivative or pharmaceutically acceptable salt thereof, method for preparing same, and pharmaceutical composition for diagnosing or treating brain degenerative diseases comprising same as active ingredient | FUTURECHEM CO LTD | 2015-05-20 | — | — | CN | disclosed |
| EP-2350311-B1 | DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS | MADRIGAL PHARMACEUTICALS INC (US) | 2013-12-25 | — | — | EP | disclosed |
| US-8575204-B2 | Nicotinamide derivates useful as P38 inhibitors | GLAXOSMITHKLINE LLC (US) | 2013-11-05 | — | — | US | disclosed |
| EP-2258687-B1 | Nicotinamide derivates useful as P38 inhibitors | GLAXOSMITHKLINE LLC (US) | 2012-12-26 | — | — | EP | disclosed |
| US-8324385-B2 | Diacylglycerol acyltransferase inhibitors | MADRIGAL PHARMACEUTICALS, INC. (US) | 2012-12-04 | — | — | US | disclosed |
| US-8324385-B2 | Diacylglycerol acyltransferase inhibitors | MADRIGAL PHARMACEUTICALS, INC. (US) | 2012-12-04 | — | — | US | disclosed |
| US-8324385-B2 | Diacylglycerol acyltransferase inhibitors | MADRIGAL PHARMACEUTICALS, INC. (US) | 2012-12-04 | — | — | US | disclosed |
| CN-102725285-A | (3-fluoro-2-hydroxy) propyl-functional aryl derivative or pharmaceutically acceptable salt thereof, method for preparing same, and pharmaceutical composition for diagnosing or treating brain degenerative diseases comprising same as active ingredient | FUTURECHEM CO LTD | 2012-10-10 | — | — | CN | disclosed |
| US-8252818-B2 | Nicotinamide derivatives useful as P38 inhibitors | GLAXOSMITHKLINE LLC (US) | 2012-08-28 | — | — | US | disclosed |
| EP-1257536-A1 | SUBSTITUTED NICOTINAMIDES AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF | Cytovia, Inc. (US) | 2002-11-20 | — | — | EP | disclosed |
| US-6458813-B1 | 2-CYCLOHEXYLOXY-5-(2-CHLOROPHENYLCARBONYLAMINO)PYRIDINE, FOR EXAMPLE; TREATING INFLAMMATION, PAIN, DIABETES, CANCER | AMGEN INC. | 2002-10-01 | — | — | US | disclosed |
| US-20020035094-A1 | Substituted pyridine compounds and methods of use | AMGEN INC. | 2002-03-21 | — | — | US | disclosed |
| US-20020010185-A1 | Substituted nicotinamides and analogs as activators of caspases and inducers of apoptosis and the use thereof | CYTOVIA, INC. | 2002-01-24 | — | — | US | disclosed |
| US-6333341-B1 | TUMOR NECROSIS FACTOR, ANTIINFLAMMATORY AGENTS AND ANALGESICS | AMGEN INC. | 2001-12-25 | — | — | US | disclosed |
| WO-2001055115-A1 | SUBSTITUTED NICOTINAMIDES AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF | CYTOVIA, INC. (US) | 2001-08-02 | — | — | WO | disclosed |
| US-6184237-B1 | Substituted pyridine compounds and methods of use | AMGEN INC. | 2001-02-06 | — | — | US | disclosed |
| EP-1028945-A1 | SUBSTITUTED PYRIDINE COMPOUNDS AS ANTI-INFLAMMATORY AGENTS | Amgen Inc. (US) | 2000-08-23 | — | — | EP | disclosed |
| US-6022884-A | PROPHYLAXIS OR TREATMENT OF INFLAMMATION | AMGEN INC. (US) | 2000-02-08 | — | — | US | disclosed |
| WO-1999024404-A1 | SUBSTITUTED PYRIDINE COMPOUNDS AS ANTI-INFLAMMATORY AGENTS | AMGEN INC. (US) | 1999-05-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020010185-A1 | Substituted nicotinamides and analogs as activators of caspases and inducers of apoptosis and the use thereof | CASP3, BAD, CASP12 | RAB9A 1146/4885SMN1; SMN2 2117/4885P4HTM 2883/4885 |
| US-20020035094-A1 | Substituted pyridine compounds and methods of use | IL1B, IL6, IL1A | RAB9A 2767/4885SMN1; SMN2 2578/4885P4HTM 402/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.